References
- López-Muñoz F, Alamo C. The consolidation of neuroleptic therapy: Janssen, the discovery of haloperidol and its introduction into clinical practice. Brain Res Bull. 2009; 792:130–141. DOI: https://doi.org/10.1016/j.brainresbull.2009.01.005.
- Hálfdánarson Ó, Zoëga H, Aagaard L, et al. International trends in antipsychotic use: a study in 16 countries, 2005-2014. Eur Neuropsychopharmacol. 2017;27(10):1064–1076. DOI:https://doi.org/10.1016/j.euroneuro.2017.07.001.
- Lako IM, van den Heuvel ER, Knegtering H, et al. Estimating dopamine D₂ receptor occupancy for doses of 8 antipsychotics: a meta-analysis. J Clin Psychopharmacol. 2013;33(5):675–681. DOI:https://doi.org/10.1097/JCP.0b013e3182983ffa.
- Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939–951. DOI:https://doi.org/10.1016/S0140-6736(19)31135-3.
- Cipriani A, Barbui C, Salanti G, et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet. 2011;378(9799):1306–1315. DOI:https://doi.org/10.1016/S0140-6736(11)60873-8.
- Yildiz A, Nikodem M, Vieta E, et al. A network meta-analysis on comparative efficacy and all-cause discontinuation of antimanic treatments in acute bipolar mania. Psychol Med. 2015;45(2):299–317. DOI:https://doi.org/10.1017/S0033291714001305.
- Keck PEJ, McElroy SL. Clinical pharmacodynamics and pharmacokinetics of antimanic and mood-stabilizing medications. J Clin Psychiatry. 2002;63(Suppl 4):3–11.
- Lin P, Zhang J, Shi F, et al. Can haloperidol prophylaxis reduce the incidence of delirium in critically ill patients in intensive care units? A systematic review and meta-analysis. Heart Lung. 2020;49(3):265–272. DOI:https://doi.org/10.1016/j.hrtlng.2020.01.010.
- Wu YC, Tseng PT, Tu YK, et al. Association of delirium response and safety of pharmacological interventions for the management and prevention of delirium: a network meta-analysis. JAMA Psychiatry. 2019;76(5):526–535. DOI:https://doi.org/10.1001/jamapsychiatry.2018.4365.
- Girard TD, Exline MC, Carson SS, et al. Haloperidol and ziprasidone for treatment of delirium in critical Illness. N Engl J Med. 2018;379(26):2506–2516. DOI:https://doi.org/10.1056/NEJMoa1808217.
- Maldonado JR. Neuropathogenesis of delirium: review of current etiologic theories and common pathways. Am J Geriatr Psychiatry. 2013;21(12):1190–1222.
- Zaporowska-Stachowiak I, Stachowiak-Szymczak K, Oduah MT, et al. Haloperidol in palliative care: indications and risks. Biomed Pharmacother. 2020;132:110772.
- Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000;68(1):29–39.
- Lehmann DF, Eggleston WD, Wang D. Validation and clinical utility of the hERG IC50:C max ratio to determine the risk of drug-induced torsades de pointes: a meta-analysis. Pharmacotherapy. 2018;38(3):341–348.
- Froemming JS, Lam YW, Jann MW, et al. Pharmacokinetics of haloperidol. Clin Pharmacokinet. 1989;17(6):396–423. DOI:https://doi.org/10.2165/00003088-198917060-00004.
- Kudo S, Ishizaki T. Pharmacokinetics of haloperidol: an update. Clin Pharmacokinet. 1999;37(6):435–456.
- Franken LG, de Winter BC, van Esch HJ, et al. Pharmacokinetic considerations and recommendations in palliative care, with focus on morphine, midazolam and haloperidol. Expert Opin Drug Metab Toxicol. 2016;12(6):669–680. DOI:https://doi.org/10.1080/17425255.2016.1179281.
- de Leon J, Diaz FJ, Wedlund P, et al. Haloperidol half-life after chronic dosing. J Clin Psychopharmacol. 2004;24(6):656–660. DOI:https://doi.org/10.1097/01.jcp.0000145340.53417.ca.
- Avent KM, DeVoss JJ, Gillam EM. Cytochrome P450-mediated metabolism of haloperidol and reduced haloperidol to pyridinium metabolites. Chem Res Toxicol. 2006;19(7):914–920.
- Pan L, Belpaire FM. In vitro study on the involvement of CYP1A2, CYP2D6 and CYP3A4 in the metabolism of haloperidol and reduced haloperidol. Eur J Clin Pharmacol. 1999;55(8):599–604.
- Kato Y, Nakajima M, Oda S, et al. Human UDP-glucuronosyltransferase isoforms involved in haloperidol glucuronidation and quantitative estimation of their contribution. Drug Metab Dispos. 2012;40(2):240–248. DOI:https://doi.org/10.1124/dmd.111.042150.
- de Leon J. Glucuronidation enzymes, genes and psychiatry. Int J Neuropsychopharmacol. 2003;6(1):57–72.
- Kirchheiner J, Nickchen K, Bauer M, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry. 2004;9(5):442–473. DOI:https://doi.org/10.1038/sj.mp.4001494.
- de Leon J, Armstrong SC, Cozza KL. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics. 2006;47(1):75–85.
- Bousman CA, Bengesser SA, Aitchison KJ, et al. Review and consensus on pharmacogenomic testing in psychiatry. Pharmacopsychiatry. 2021;54(1):5–17. DOI:https://doi.org/10.1055/a-1288-1061. You have deleted reference 26. I cannot find a way to add. Please see attached Word list
- The Dutch Pharmacogenomic Working Group 2021. Phamacogenomic recommendations, farmacogenetica-update. Available at: www.knmp.nl/ (Accessed July 18, 2021)
- Milosavljevic F, Bukvic N, Pavlovic Z, et al. Association of CYP2C19 and CYP2D6 poor and intermediate metabolizer status with antidepressant and antipsychotic exposure: a systematic review and meta-analysis. JAMA Psychiatry. 2021;78(3):270–280. DOI:https://doi.org/10.1001/jamapsychiatry.2020.3643. This is reference 27
- Zheng M, Zhang H, Dill DL, et al. The role of Abcb5 alleles in susceptibility to haloperidol-induced toxicity in mice and humans. PLoS Med. 2015;12(2):e1001782. DOI:https://doi.org/10.1371/journal.pmed.1001782. This is 28
- Iwaki K, Sakaeda T, Kakumoto M, et al. Haloperidol is an inhibitor but not substrate for MDR1/P-glycoprotein. J Pharm Pharmacol. 2010;58(12):1617–1622. DOI:https://doi.org/10.1211/jpp.58.12.0008. This is 29
- Zhou S, Zeng S, Shu Y. Drug-drug interactions at organic cation transporter 1. Front Pharmacol. 2021;12:628705 This is 30 .
- Rueda-Vasquez E. Outcome of treatment with haloperidol decanoate in a patient with schizophrenia, chronic undifferentiated type, and end stage renal disease. Mil Med. 1988;153:595.
- Khot V, DeVane CL, Korpi ER, et al. The assessment and clinical implications of haloperidol acute-dose, steady-state, and withdrawal pharmacokinetics. J Clin Psychopharmacol. 1993;13(2):120–127. DOI:https://doi.org/10.1097/00004714-199304000-00006.
- Midha KK, Chakraborty BS, Ganes DA, et al. Intersubject variation in the pharmacokinetics of haloperidol and reduced haloperidol. J Clin Psychopharmacol. 1989;9(2):98–104. DOI:https://doi.org/10.1097/00004714-198904000-00005.
- Ereshefsky L, Davis CM, Harrington CA, et al. Haloperidol and reduced haloperidol plasma levels in selected schizophrenia patients. J Clin Psychopharmacol. 1984;4(3):138–142. DOI:https://doi.org/10.1097/00004714-198406000-00005.
- Čolić A, Alessandrini M, Pepper MS. Pharmacogenetics of CYP2B6, CYP2A6 and UGT2B7 in HIV treatment in African populations: focus on efavirenz and nevirapine. Drug Metab Rev. 2015;47(2):111–123.
- Bauer LA. Clinical pharmacokinetic and pharmacodynamic concepts. In: editor, Bauer LA. Applied clinical pharmacokinetics. 3rd ed. New York (NY): McGraw Hill; 2014. p. 15.
- Hiemke C, Bergemann N, Clement HW, et al. Consensus guidelines for therapeutic drug monitoring in Neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51(1/2):9–62. DOI:https://doi.org/10.1055/s-0043-116492.
- Ulrich S, Braun V, Meyer F. Therapeutic window of serum haloperidol concentration in acute schizophrenia and schizoaffective disorder. Pharmacopsychiatry. 1998;31(5):163–169. DOI:https://doi.org/10.1055/s-2007-979322.
- Balant-Gorgia A, Eisele R, Balant L, et al., Plasma haloperidol levels and therapeutic response in acute mania and schizophrenia. Eur Arch Psychiatry Neurol Sci. 234(1): 1–4. 1984. . DOI: https://doi.org/10.1007/BF00432875.
- Pelton G, Devanand D, Marder K. Usefulness of plasma haloperidol levels in monitoring clinical efficacy and side effects in Alzheimer patients with psychosis and behavioral dyscontrol. Am J Geriatr Psychiatry. 2003;11:186–193.
- van Schijndel AW, Franssen EJF, Pickkers P, et al. Haloperidol serum concentrations in critically ill patients included in the REDUCE study. Intensive Care medicine. 2018;44(10):1774–1775. DOI:https://doi.org/10.1007/s00134-018-5348-9.
- Spina E, Hiemke C, de Leon J. Assessing drug-drug interactions through therapeutic drug monitoring when administering oral second-generation antipsychotics. Expert Opin Drug Metab Toxicol. 2016;12(4):407–422. DOI:https://doi.org/10.1517/17425255.2016.1154043.
- Forsman A, Larsson M. Metabolism of haloperidol. Curr Ther Res. 1978;24:567–568.
- Forsman A, Ohman R. Interindividual variation of clinical response to haloperidol. In: Obiols J, Ballus C, Gonzalez Monclus E, et al. editors. Biological psychiatry today, 1978. Proceedings of the 2nd World Congress on Biological Psychiatry held from August 31st to September 6th, 1978, in Barcelona, Spain (Developments in psychiatry). Amsterdam: 1979, Elsevier/North-Holland Biomedical Press; p 949–954.
- Altamura C, Mauri M, Cavallaro R, et al. Reduced haloperidol/haloperidol ratio and clinical outcome in schizophrenia: preliminary evidences. Prog Neuropsychopharmacol Biol Psychiatry. 1988;12(5):689–694. DOI:https://doi.org/10.1016/0278-5846(88)90013-9.
- European Medicine Agency. Guideline on the investigation of drug interactions. London, UK. 2012 June 12; https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-drug-interactions-revision-1_en.pdf
- Polasek TM, Lin FP, Miners JO, et al. Perpetrators of pharmacokinetic drug-drug interactions arising from altered cytochrome P450 activity: a criteria-based assessment. Br J Clin Pharmacol. 2011;71(5):727–736. DOI:https://doi.org/10.1111/j.1365-2125.2011.03903.x.
- Schoretsanitis G, Spina E, Hiemke C, et al. A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting risperidone. Expert Rev Clin Pharmacol. 2017;10(9):965–981. DOI:https://doi.org/10.1080/17512433.2017.1345623.
- Schoretsanitis G, Spina E, Hiemke C, et al. A systematic review and combined analysis of therapeutic drug monitoring studies for oral paliperidone. Expert Rev Clin Pharmacol. 2018;11(6):625–639. DOI:https://doi.org/10.1080/17512433.2018.1478727.
- Schoretsanitis G, Spina E, Hiemke C, et al. A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting paliperidone. Expert Rev Clin Pharmacol. 2018;11(12):1237–1253. DOI:https://doi.org/10.1080/17512433.2018.1549489.
- Schoretsanitis G, Kane JM, Ruan CJ, et al. A comprehensive review of the clinical utility of and a combined analysis of the clozapine/norclozapine ratio in therapeutic drug monitoring for adult patients. Expert Rev Clin Pharmacol. 2019;12(7):603–621. DOI:https://doi.org/10.1080/17512433.2019.1617695.
- Shapiro S. Is meta-analysis a valid approach to the evaluation of small effects in observational studies? J Clin Epidemiol. 1997;50:223–229.
- de Leon J. Psychopharmacology: atypical antipsychotic dosing: the effect of co-medication with anticonvulsants. Psychiatr Serv. 2004;55(2):125–128.
- de Leon J. Atypical antipsychotic dosing: the effect of smoking and caffeine. Psychiatr Serv. 2004;55(5):491–493.
- de Leon J, Armstrong SC, Cozza KL. The dosing of atypical antipsychotics. Psychosomatics. 2005;46(3):262–273.
- Stout SM, Nemerovski CW, Streetman DS, et al. Interpretation of cytochrome P-450 inhibition and induction effects from clinical data: current standards and recommendations for implementation. Clin Pharmacol Ther. 2021;109(1):82–86. DOI:https://doi.org/10.1002/cpt.1918.
- Yasui-Furukori N, Kondo T, Mihara K, et al. Significant dose effect of carbamazepine on reduction of steady-state plasma concentration of haloperidol in schizophrenic patients. J Clin Psychopharmacol. 2003;23:435–440.
- Arana GW, Goff DC, Friedman H, et al. Does carbamazepine-induced reduction of plasma haloperidol levels worsen psychotic symptoms? Am J Psychiatry. 1986;143:650–651.
- Kidron R, Averbuch I, Klein E, et al. Carbamazepine-induced reduction of blood levels of haloperidol in chronic schizophrenia. Biol Psychiatry. 1985;20(2):219–222. DOI:https://doi.org/10.1016/0006-3223(85)90087-3.
- Jann MW, Ereshefsky L, Saklad SR, et al. Effects of carbamazepine on plasma haloperidol levels. J Clin Psychopharmacol. 1985;5:106–109.
- Jann MW, Fidone GS, Hernandez JM, et al. Clinical implications of increased antipsychotic plasma concentrations upon anticonvulsant cessation. Psychiatry Res. 1989;28(2):153–159. DOI:https://doi.org/10.1016/0165-1781(89)90043-7.
- Linnoila M, Viukari M, Vaisanen K, et al. Effect of anticonvulsants on plasma haloperidol and thioridazine levels. Am J Psychiatry. 1980;137:819–821.
- Kim Y-H, Cha I-J, Shim J-C, et al. Effect of rifampin on the plasma concentration and the clinical effect of haloperidol concomitantly administered to schizophrenic patients. J Clin Psychopharmacol. 1996;16(3):247–252. DOI:https://doi.org/10.1097/00004714-199606000-00010.
- Raitasuo V, Lehtovaara R, Huttunen MO. Effect of switching carbamazepine to oxcarbazepine on the plasma levels of neuroleptics case report. Psychopharmacology (Berl). 1994;116(1):115–116.
- Tiihonen J, Vartiainen H, Hakola P. Carbamazepine-induced changes in plasma levels of neuroleptics. Pharmacopsychiatry. 1995;28(1):26–28.
- de Leon J. The effects of antiepileptic inducers in neuropsychopharmacology, a neglected issue. part I: a summary of the current state for clinicians. Rev Psiquiatr Salud Ment. 2015;8(2):97–115.
- McGrane IR, Loveland JG, de Leon J. Possible oxcarbazepine inductive effects on aripiprazole metabolism: a case report. J Pharm Pract. 2018;31(3):361–363.
- Suzuki A, Yasui-Furukori N, Mihara K, et al. Histamine H1-receptor antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol. Ther Drug Monit. 2003;25(2):192–196. DOI:https://doi.org/10.1097/00007691-200304000-00008.
- Harrigan EP, Miceli JJ, Anziano R, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol. 2004;24(1):62–69. DOI:https://doi.org/10.1097/01.jcp.0000104913.75206.62.
- Barbhaiya RH, Shukla UA, Greene DS, et al. Investigation of pharmacokinetic and pharmacodynamic interactions after coadministration of nefazodone and haloperidol. J Clin Psychopharmacol. 1996;16(1):26–34. DOI:https://doi.org/10.1097/00004714-199602000-00005.
- Lee MS, Han CS, You YW, et al. Co-administration of sertraline and haloperidol. Psychiatry Clin Neurosci. 1998;52(S6):S193–198. DOI:https://doi.org/10.1111/j.1440-1819.1998.tb03220.x.
- Hesslinger B, Normann C, Langosch JM, et al. Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients. J Clin Psychopharmacol. 1999;19(4):310–315. DOI:https://doi.org/10.1097/00004714-199908000-00005.
- Goff DC, Midha KK, Brotman AW, et al. An open trial of buspirone added to neuroleptics in schizophrenic patients. J Clin Psychopharmacol. 1991;11(3):193–197. DOI:https://doi.org/10.1097/00004714-199106000-00008.
- Huang HF, Jann MW, Wei FC, et al. Lack of pharmacokinetic interaction between buspirone and haloperidol in patients with schizophrenia. J Clin Pharmacol. 1996;36(10):963–969. DOI:https://doi.org/10.1002/j.1552-4604.1996.tb04764.x.
- Avenoso A, Spinà E, Campo G, et al. Interaction between fluoxetine and haloperidol: pharmacokinetic and clinical implications. Pharmacol Res. 1997;35(4):335–339. DOI:https://doi.org/10.1006/S1043-6618(97)90144-5.
- Shim JC, Kelly DL, Kim YH, et al. Fluoxetine augmentation of haloperidol in chronic schizophrenia. J Clin Psychopharmacol. 2003;23(5):520–522. DOI:https://doi.org/10.1097/01.jcp.0000088912.24613.d6.
- Yasui N, Kondo T, Otani K, et al. Effects of itraconazole on the steady-state plasma concentrations of haloperidol and its reduced metabolite in schizophrenic patients: in vivo evidence of the involvement of CYP3A4 for haloperidol metabolism. J Clin Psychopharmacol. 1999;19(2):149–154. DOI:https://doi.org/10.1097/00004714-199904000-00010.
- Park JY, Shon JH, Kim KA, et al. Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects. J Clin Psychopharmacol. 2006;26(2):135–142. DOI:https://doi.org/10.1097/01.jcp.0000203199.88581.c3.
- Vandel S, Bertschy G, Baumann P, et al. Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. Pharmacol Res. 1995;31(6):347–353. DOI:https://doi.org/10.1016/1043-6618(95)80088-3.
- Daniel DG, Randolph C, Jaskiw G, et al. Coadministration of fluvoxamine increases serum concentrations of haloperidol. J Clin Psychopharmacol. 1994;14(5):340–343. DOI:https://doi.org/10.1097/00004714-199410000-00009.
- Yasui-Furukori N, Kondo T, Mihara K, et al. Fluvoxamine dose-dependent interaction with haloperidol and the effects on negative symptoms in schizophrenia. Psychopharmacology (Berl). 2004;171(2):223–227. DOI:https://doi.org/10.1007/s00213-003-1567-y.
- Jann MW, Saklad SR, Ereshefsky L, et al. Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance. Psychopharmacology (Berl). 1986;90(4):468–470. DOI:https://doi.org/10.1007/BF00174062.
- Miller DD, Kelly MW, Perry PJ, et al. The influence of cigarette smoking on haloperidol pharmacokinetics. Biol Psychiatry. 1990;28(6):529–531. DOI:https://doi.org/10.1016/0006-3223(90)90488-N.
- Perry PJ, Miller DD, Arndt SV, et al. Haloperidol dosing requirements: the contribution of smoking and nonlinear pharmacokinetics. J Clin Psychopharmacol. 1993;13(1):46–51. DOI:https://doi.org/10.1097/00004714-199302000-00006.
- Shimoda K, Someya T, Morita S, et al. Lower plasma levels of haloperidol in smoking than in nonsmoking schizophrenic patients. Ther Drug Monit. 1999;21(3):293–296. DOI:https://doi.org/10.1097/00007691-199906000-00006.
- Yasui N, Kondo T, Suzuki A, et al. Lack of significant pharmacokinetic interaction between haloperidol and grapefruit juice. Int Clin Psychopharmacol. 1999;14(2):113–118. DOI:https://doi.org/10.1097/00004850-199903000-00008.
- Mihara K, Suzuki A, Kondo T, et al. Effect of a genetic polymorphism of CYP1A2 inducibility on the steady state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia. Ther Drug Monit. 2000;22(3):245–249. DOI:https://doi.org/10.1097/00007691-200006000-00002.
- Ohara K, Tanabu S, Yoshida K, et al. Effects of smoking and cytochrome P450 2D6*10 allele on the plasma haloperidol concentration/dose ratio. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(6):945–949. DOI:https://doi.org/10.1016/S0278-5846(03)00154-4.
- Douyon R, Angrist B, Peselow E, et al. Neuroleptic augmentation with alprazolam: clinical effects and pharmacokinetic correlates. Am J Psychiatry. 1989;146:231–234.
- Calil HM, Avery DH, Hollister LE, et al. Serum levels of neuroleptics measured by dopamine radioreceptor assay and some clinical observations. Psychiatry Res. 1979;1(1):39–44. DOI:https://doi.org/10.1016/0165-1781(79)90026-X.
- Suzuki Y, Someya T, Shimoda K, et al. Importance of the cytochrome P450 2D6 genotype for the drug metabolic interaction between chlorpromazine and haloperidol. Ther Drug Monit. 2001;23(4):363–368. DOI:https://doi.org/10.1097/00007691-200108000-00007.
- Syvalahti EK, Taiminen T, Saarijarvi S, et al. Citalopram causes no significant alterations in plasma neuroleptic levels in schizophrenic patients. J Int Med Res. 1997;25(1):24–32. DOI:https://doi.org/10.1177/030006059702500104.
- Nemes ZC, Volavka J, Cooper TB, et al. Lithium and haloperidol. Biol Psychiatry. 1986;21(5–6):568–569. DOI:https://doi.org/10.1016/0006-3223(86)90205-2.
- Kahn EM, Schulz SC, Perel JM, et al. Change in haloperidol level due to carbamazepine--a complicating factor in combined medication for schizophrenia. J Clin Psychopharmacol. 1990;10(1):54–57. DOI:https://doi.org/10.1097/00004714-199002000-00011.
- Stevens A, Stevens I, Mahal A, et al. Haloperidol and lorazepam combined: clinical effects and drug plasma levels in the treatment of acute schizophrenic psychosis. Pharmacopsychiatry. 1992;25(6):273–277. DOI:https://doi.org/10.1055/s-2007-1014421.
- Greendyke RM, Kanter DR. Plasma propranolol levels and their effect on plasma thioridazine and haloperidol concentrations. J Clin Psychopharmacol. 1987;7(3):178–182.
- Greendyke RM, Gulya A. Effect of pindolol administration on serum levels of thioridazine, haloperidol, phenytoin, and phenobarbital. J Clin Psychiatry. 1988;49(3):105–107.
- Shin JG, Soukhova N, Flockhart DA. Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. Drug Metab Dispos. 1999;27(9):1078–1084.
- Shin JG, Kane K, Flockhart DA. Potent inhibition of CYP2D6 by haloperidol metabolites: stereoselective inhibition by reduced haloperidol. Br J Clin Pharmacol. 2001;51(1):45–52. DOI:https://doi.org/10.1046/j.1365-2125.2001.01313.x.
- Gram LF, Debruyne D, Caillard V, et al. Substantial rise in sparteine metabolic ratio during haloperidol treatment. Br J Clin Pharmacol. 1989;27(2):272–275. DOI:https://doi.org/10.1111/j.1365-2125.1989.tb05362.x.
- Spina E, Martines C, Caputi AP, et al. Debrisoquine oxidation phenotype during neuroleptic monotherapy. Eur J Clin Pharmacol. 1991;41(5):467–470. DOI:https://doi.org/10.1007/BF00626371.
- Mihara K, Otani K, Ishida M, et al. Increases in plasma concentration of m-chlorophenylpiperazine, but not trazodone, with low-dose haloperidol. Ther Drug Monit. 1997;19(1):43–45. DOI:https://doi.org/10.1097/00007691-199702000-00007.
- LLerena A, de la Rubia A, Berecz R, et al. Relationship between haloperidol plasma concentration, debrisoquine metabolic ratio, CYP2D6 and CYP2C9 genotypes in psychiatric patients. Pharmacopsychiatry. 2004;37:69–73.
- de Leon J. Evidence-based medicine versus personalized medicine: are they enemies? J Clin Psychopharmacol. 2012;32(2):153–164.
- de Leon J, Santoro V, D’Arrigo C, et al. Interactions between antiepileptics and second-generation antipsychotics. Expert Opin Drug Metab Toxicol. 2012;8(8):311–334. DOI:https://doi.org/10.1517/17425255.2012.660918.
- Spina E, de Leon J. Clinically relevant interactions between newer antidepressants and second-generation antipsychotics. Expert Opin Drug Metab Toxicol. 2014;10(5):721–746.
- Spina E, Pisani F, de Leon J. Clinically significant pharmacokinetic drug interactions of antiepileptic drugs with new antidepressants and new antipsychotics. Pharmacol Res. 2016;106:72–86.
- Spina E, Barbieri MA, Cicala G, et al. Clinically relevant interactions between atypical antipsychotics and anti-infective agents. Pharmaceuticals (Basel). 2020;13(12):439. DOI:https://doi.org/10.3390/ph13120439.
- Waade RB, Solhaug V, Høiseth G. Impact of CYP2D6 on serum concentrations of flupentixol, haloperidol, perphenazine and zuclopenthixol. Br J Clin Pharmacol. 2021;87(5):2228–2235.
- Lisbeth P, Vincent H, Kristof M, et al. Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol. Eur J Clin Pharmacol. 2016;72(2):175–184. DOI:https://doi.org/10.1007/s00228-015-1965-1.
- Potkin SG, Thyrum PT, Alva G, et al. The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine. J Clin Psychopharmacol. 2002;22:121–130.
- Satterthwaite TD, Wolf DH, Rosenheck RA, et al. A meta-analysis of the risk of acute extrapyramidal symptoms with intramuscular antipsychotics for the treatment of agitation. J Clin Psychiatry. 2008;69(12):1869–1879. DOI:https://doi.org/10.4088/JCP.v69n1204.
- de Leon J. Paying attention to pharmacokinetic and pharmacodynamic mechanisms to progress in the area of anticholinergic use in geriatric patients. Curr Drug Metab. 2011;12(7):635–646.
- Spina E, Leon J. Potentially clinically relevant pharmacodynamic interactions between antiepileptic drugs and psychotropic drugs: an update. Curr Pharm Des. 2017;23(37):5625–5638.
- de Leon J, Spina E. Possible pharmacodynamic and pharmacokinetic drug-drug interactions that are likely to be clinically relevant and/or frequent in bipolar disorder. Curr Psychiatry Rep. 2018;20(3):17.
- Wahidi N, Johnson KM, Brenzel A, et al. Two sudden and unexpected deaths of patients with schizophrenia associated with intramuscular injections of antipsychotics and practice guidelines to limit the use of high doses of intramuscular antipsychotics. Case Rep Psychiatry. 2016;2016:9406813.
- de Leon J. Why do you keep telling me that drug-drug interactions are important in psychopharmacology when I do not see them in my clinical practice?: my failure to convince clinicians. J Clin Psychopharmacol. 2019;39(1):1–4.
- de Leon J. Highlights of drug package inserts and the website dailymed: the need for further improvement in package inserts to help busy prescribers. J Clin Psychopharmacol. 2011;31(3):263–265.